Department of Neurology, University Hospital of Frankfurt, Goethe-University, Schleusenweg 2-16, 60528, Frankfurt am Main, Germany.
Department of Cardiology, King AbdulAziz Medical City Complex, Riyadh, Saudi Arabia.
J Thromb Thrombolysis. 2021 Feb;51(2):485-493. doi: 10.1007/s11239-020-02218-0.
Fasting Ramadan is known to influence patients' medication adherence. Data on patients' behavior to oral anticoagulant (OAC) drug intake during Ramadan is missing. We aimed to determine patient-guided modifications of OAC medication regimen during Ramadan and to evaluate its consequences. A multicenter cross-sectional study conducted in Saudi Arabia. Data were collected shortly after Ramadan 2019. Participants were patients who fasted Ramadan and who were on long-term anticoagulation. Patient-guided medication changes during Ramadan in comparison to the regular intake schedule before Ramadan were recorded. Modification behavior was compared between twice daily (BID) and once daily (QD) treatment regimens. Rates of hospital admission during Ramadan were determined. We included 808 patients. During Ramadan, 53.1% modified their intake schedule (31.1% adjusted intake time, 13.2% skipped intakes, 2.2% took double dosing). A higher frequency of patient-guided modification was observed in patients on BID regimen compared to QD regimen. During Ramadan, 11.3% of patients were admitted to hospital. Patient-guided modification was a strong predictor for hospital admission. Patient-guided modification of OAC intake during Ramadan is common, particularly in patients on BID regimen. It increases the risk of hospital admission during Ramadan. Planning of OAC intake during Ramadan and patient education on the risk of low adherence are advisable.
斋戒拉马丹被认为会影响患者对药物的依从性。关于拉马丹期间患者口服抗凝药物(OAC)药物摄入行为的数据尚不清楚。我们旨在确定患者在拉马丹期间对 OAC 药物治疗方案的指导修改,并评估其后果。这是一项在沙特阿拉伯进行的多中心横断面研究。数据是在 2019 年拉马丹结束后不久收集的。参与者是斋戒拉马丹的长期抗凝治疗患者。记录了拉马丹期间与常规摄入时间表相比患者指导的药物变化。比较了每日两次(BID)和每日一次(QD)治疗方案之间的修改行为。还确定了拉马丹期间住院的发生率。我们共纳入 808 例患者。在拉马丹期间,53.1%的患者修改了他们的摄入时间表(31.1%调整了摄入时间,13.2%跳过了摄入,2.2%服用了双倍剂量)。与 QD 方案相比,BID 方案的患者更频繁地进行了患者指导的修改。在拉马丹期间,11.3%的患者住院。患者指导的修改是住院的强烈预测因素。拉马丹期间 OAC 摄入的患者指导修改很常见,尤其是在 BID 方案的患者中。它增加了拉马丹期间住院的风险。建议在拉马丹期间计划 OAC 摄入,并对低依从性的风险对患者进行教育。